ATEC Stock Analysis: Alphatec Holdings | NASDAQ
Medical Devices | NASDAQ, USA | Market Cap: 1.435m USD | 12M Return: -17.3% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 27.3M
Qual. Beats: -1
Rev. Trend: 99.9%
Qual. Beats: -1
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Alphatec Holdings (ATEC) is a Carlsbad, California-based medical technology company founded in 1990 that designs, manufactures, and sells implants, instruments, imaging equipment, and spare parts used in the surgical treatment of spinal disorders across the U.S. and international markets. Its product portfolio spans three main areas: the Alpha InformatiX platform (which includes the EOS full-body imaging system, the SafeOp neural monitoring system, and the Valence intra-operative navigation and robotics system), a range of procedural access systems and fixation products (such as Sigma PTP, Sigma-ALIF, NanoTec, and Invictus), and a biologics line that includes osteoconductive scaffolds, demineralized bone matrix products, cellular bone matrices, and amniotic tissue barriers. The company distributes its products through a combination of independent sales agents and direct sales representatives.
ATEC operates within the medical device industry, specifically the spinal surgery segment, which is generally regarded as one of the more specialized and technologically intensive corners of the broader orthopedic market. Its integration of imaging, neural monitoring, navigation, and robotics within a single procedural ecosystem reflects the industrys broader shift toward digital and computer-assisted spine surgery, while its biologics offering addresses the longstanding need to improve fusion outcomes and reduce complication rates in spinal procedures.
- Spine surgery revenue growth accelerates on new product adoption
- Path to profitability improves as operating leverage expands margins
- Competition intensifies from larger spine medtech peers pressuring share
| Net Income: -125.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA 11.14 > 1.0 |
| NWC/Revenue: 27.43% < 20% (prev 43.13%; Δ -15.70% < -1%) |
| CFO/TA 0.06 > 3% & CFO 51.6m > Net Income -125.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.90 > 1.5 & < 3 |
| Outstanding Shares: last quarter (154.1m) vs 12m ago 4.99% < -2% |
| Gross Margin: 65.32% > 18% (prev 68.96%; Δ -3.64% > 0.5%) |
| Asset Turnover: 99.32% > 50% (prev 81.77%; Δ 17.55% > 0%) |
| Interest Coverage Ratio: -1.98 > 6 (EBIT TTM -83.2m / Interest Expense TTM 42.1m) |
| A: 0.27 (Total Current Assets 456.2m - Total Current Liabilities 240.2m) / Total Assets 799.5m |
| B: -1.82 (Retained Earnings -1.46b / Total Assets 799.5m) |
| C: -0.10 (EBIT TTM -83.2m / Avg Total Assets 792.5m) |
| D: 0.02 (Book Value of Equity 18.3m / Total Liabilities 781.2m) |
| Altman-Z'' = -4.86 = D |
| DSRI: 0.99 (Receivables 112.8m/92.8m, Revenue 787.1m/642.3m) |
| GMI: 1.06 (GM 68.96% / 65.32%) |
| AQI: 1.01 (AQ_t 0.22 / AQ_t-1 0.22) |
| SGI: 1.23 (Revenue 787.1m / 642.3m) |
| TATA: -0.22 (NI -125.4m - CFO 51.6m) / TA 799.5m) |
| Beneish M = -2.84 (Cap -4..+1) = A |
As of July 11, 2026, the stock is trading at USD 9.58 with a total of 1,403,776 shares traded. Over the past week, the price has changed by +7.40%, over one month by +17.84%, over three months by -12.11% and over the past year by -17.27%.
Current recommended Stop Loss: 8.60 (which is 10.2% or 2 ATR below the current price).
Alphatec Holdings has received a consensus analysts rating of 4.30. Therefore, it is recommended to buy ATEC.
- StrongBuy: 4
- Buy: 5
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 16.7 | 74.6% |
P/E Forward = 357.1429
P/S = 1.823
P/B = 126.5491
P/EG = 0.4838
Revenue TTM = 787.1m USD
EBIT TTM = -83.2m USD
EBITDA TTM = -1.35m USD
Long Term Debt = 507.9m USD (from longTermDebt, last quarter)
Short Term Debt = 72.2m USD (from shortTermDebt, last quarter)
Debt = 632.7m USD (from shortLongTermDebtTotal, last quarter) + Leases 29.6m
Net Debt = 492.8m USD (calculated: Debt 632.7m - CCE 139.9m)
Enterprise Value = 1.93b USD (1.43b + Debt 632.7m - CCE 139.9m)
Interest Coverage Ratio = -1.98 (Ebit TTM -83.2m / Interest Expense TTM 42.1m)
EV/FCF = 277.4x (Enterprise Value 1.93b / FCF TTM 6.95m)
FCF Yield = 0.36% (FCF TTM 6.95m / Enterprise Value 1.93b)
FCF Margin = 0.88% (FCF TTM 6.95m / Revenue TTM 787.1m)
Net Margin = -15.93% (Net Income TTM -125.4m / Revenue TTM 787.1m)
Gross Margin = 65.32% ((Revenue TTM 787.1m - Cost of Revenue TTM 273.0m) / Revenue TTM)
Gross Margin QoQ = 61.08% (prev 61.24%)
Tobins Q-Ratio = 2.41 (Enterprise Value 1.93b / Total Assets 799.5m)
Interest Expense / Debt = 6.65% (Interest Expense 42.1m / Debt 632.7m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -65.7m (EBIT -83.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.90 (Total Current Assets 456.2m / Total Current Liabilities 240.2m)
Debt / Equity = 34.66 (Debt 632.7m / totalStockholderEquity, last quarter 18.3m)
Debt / EBITDA = -363.7 (out of range, set to none) (Net Debt 492.8m / EBITDA -1.35m)
Debt / FCF = 70.92 (Net Debt 492.8m / FCF TTM 6.95m)
Total Stockholder Equity = 28.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -15.82% (Net Income -125.4m / Total Assets 799.5m)
RoE = -443.1% (Net Income TTM -125.4m / Total Stockholder Equity 28.3m)
RoCE = -15.52% (EBIT -83.2m / Capital Employed (Equity 28.3m + L.T.Debt 507.9m))
RoIC = -11.10% (negative operating profit) (NOPAT -65.7m / Invested Capital 592.0m)
WACC = 8.61% (E(1.43b)/V(2.07b) * Re(10.09%) + D(632.7m)/V(2.07b) * Rd(6.65%) * (1-Tc(0.21)))
Discount Rate = 10.09% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 91.11 | Cagr: 6.48%
[DCF] Terminal Value 74.53% ; FCFF base≈6.95m ; Y1≈6.98m ; Y5≈7.39m
[DCF] Fair Price = N/A (negative equity: EV 110.1m - Net Debt 492.8m = -382.7m; debt exceeds intrinsic value)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -4.0 | # QB: -1
Revenue Correlation: 99.87 | Revenue CAGR: 26.01% | SUE: -0.95 | # QB: -1
EPS current Quarter (2026-06-30): EPS=0.07 | Chg30d=+11.69% | Revisions=+38% | Analysts=8
EPS next Quarter (2026-09-30): EPS=0.09 | Chg30d=+9.89% | Revisions=+17% | Analysts=8
EPS current Year (2026-12-31): EPS=0.32 | Chg30d=+11.25% | Revisions=+44% | GrowthEPS=+538.7% | GrowthRev=+15.5%
EPS next Year (2027-12-31): EPS=0.58 | Chg30d=+0.49% | Revisions=-30% | GrowthEPS=+80.9% | GrowthRev=+16.6%
[Analyst] Revisions Ratio: +21% (up=13, down=8)